Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., Dec. 9, 2015 /PRNewswire/ -- Astellas today announced that results from the pivotal Phase 3 SECURE trial evaluating CRESEMBA® (isavuconazonium sulfate) in adult patients with...
-- Updated results evaluating safety, tolerability and antileukemic activity of gilteritinib in AML, a rare, aggressive blood cancer, presented at American Society of Hematology annual meeting --...
Moburg to lead stakeholder engagement initiatives in the U.S. and in support of the Americas NORTHBROOK, IL, Dec. 3, 2015 — Astellas Pharma recently announced that Christeen Moburg has been...
Read more about Christeen Moburg joins Astellas Pharma Corporate Affairs Team
November’s Bladder Health Month (#NovBHealth) Activities Aim to Raise Awareness and Reduce the Embarrassment of Bladder Issues Baltimore, MD, November 23, 2015—During Bladder Health Month, The...
NORTHBROOK, Ill., Nov. 17, 2015 /PRNewswire/ -- Astellas US, LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced several abstracts, including an oral presentation...
Read more about Astellas Announces New Data to be Presented at the 2015 ASH Annual Meeting
Follow U.S. news
